Food Science and Biotechnology

  • 제15권3호
  • /
  • Pages.413-417
  • /
  • 2006
  • /
  • 1226-7708(pISSN)
  • /
  • 2092-6456(eISSN)
한국식품과학회 (Korean Society of Food Science and Technology)
권호 표지

The Hypoglycemic Effect of Saururus chinensis Baill in Animal Models of Diabetes Mellitus

  • Joo, Hee-Jeong (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University) ;
  • Kang, Ming-Jung (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University) ;
  • Seo, Tae-Jin (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University) ;
  • Kim, Hyun-A (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University) ;
  • Yoo, Sung-Ja (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University) ;
  • Lee, Soo-Kyung (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University) ;
  • Lim, Hwa-Jae (Department of Food and Nutrition, Dong-eui University) ;
  • Byun, Boo-Hyeong (Department of Oriental Medicine, Daegu Haany University) ;
  • Kim, Jung-In (Biohealth Product Research Center, School of Food and Life Science, Institute for Food Sciences, Inje University)
  • 발행 : 2006.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of this study was to investigate the hypoglycemic effect of Saururus chinensis Baill in vitro and in vivo. Methanol extract of S. chinensis Baill inhibited yeast ${\alpha}$-glucosidase activity by 49.8%, which was twice as strong as that of acarbose at a concentration of 0.5 mg/mL in vitro. The effect of S. chinensis Baill methanol extract on the postprandial increase in blood glucose levels was studied in streptozotocin-induced diabetic rats using a carbohydrate load test. Oral administration of S. chinensis Baill extract (500 mg/kg) significantly decreased incremental blood glucose levels at 60 and 90 min (p<0.05) after oral ingestion of starch (1 g/kg). The area under the glucose response curve of the S. chinensis Baill group was significantly decreased compared to that of the control group (p<0.05). The effect of prolonged feeding of S. chinensis Baill was studied in an animal model of type 2 diabetes. Three-week-old db/db mice were fed an AIN-93G diet or a diet containing 0.5% S. chinensis Baill extract for 7 weeks after 1 week of adaptation. Plasma glucose, insulin, and blood glycated hemoglobin levels of the mice fed S. chinensis Baill extract were significantly lower than those of the control group (p<0.05). Therefore, we conclude that S. chinensis Baill is effective in controlling hyperglycemia in animal models of diabetes mellitus.

키워드

참고문헌

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025 Prevalence, numerical estimates and projections. Diabetes Care 21: 1414-1431 (1998) https://doi.org/10.2337/diacare.21.9.1414
  2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329: 977-986 (1993) https://doi.org/10.1056/NEJM199309303291401
  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352: 837-853 (1998) https://doi.org/10.1016/S0140-6736(98)07019-6
  4. Stand E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes. Metab. 1: 215-220 (1999) https://doi.org/10.1046/j.1463-1326.1999.00021.x
  5. Saito N, Sakai H, Sekihara H, Yajima Y. Effect of an ${\alpha}$-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes subjects. J. Int. Med. Res. 26: 219-232 (1998) https://doi.org/10.1177/030006059802600501
  6. Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin. Pharmaco. 1: 149-156 (1999) https://doi.org/10.1517/14656566.1.1.149
  7. Hanefeld M. The Role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J. Diabetes Complicat. 12: 228-237 (1998) https://doi.org/10.1016/S1056-8727(97)00123-2
  8. Matsui T, Yoshimoto C, Osajima K, Oki T, Osajima Y, Oki T, Osajima Y. In vitro survey of ${\alpha}$-glucosidase inhibitory food components. Biosci. Biotechnol. Biochem. 60: 2019-2022 (1996) https://doi.org/10.1271/bbb.60.2019
  9. Watanabe J, Kawabata J, Kurihara H, Niki R. Isolation and identification of ${\alpha}$-glucosidase inhibitors from Tochu-cha (Encommia ulmoides). Biosci. Biotechnol. Biochem. 61: 177-178 (1997) https://doi.org/10.1271/bbb.61.177
  10. Fujita H, Yamagami T, Ohshima K. Fermented soybean-derived touchi extract with anti-glycaemic effect via ${\alpha}$-glucosidase inhibitory action in rats and humans. J. Nutr. 131: 1211-1213 (2001)
  11. Chung BS, Shin MG. Dictionary of Korean Folk Medicine. Young Lim Sa, Seoul, Korea. p. 813 (1990)
  12. Lee WS, Baek Y-I, Kim J-R, Cho K-H, Sok D-E, Jeong T-S. Antioxidant activities of a new lignan and a neolignan from Saururus chinensis. Bioorg. Med. Chem. Lett. 14: 5623-5628 (2004) https://doi.org/10.1016/j.bmcl.2004.08.054
  13. Choi CW, Kim SC, Hwang SS, Choi BK, Ahn HJ, Lee MY, Park SH, Kim SK. Antioxidant activity and free radical scavenging capacity between Korean medicinal plants and flavonoids by assay-guided comparison. Plant Sci. 163: 1161-1168 (2002) https://doi.org/10.1016/S0168-9452(02)00332-1
  14. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA, Matsuhisa M, Yamasaki Y. Role af oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic ${\beta}$-cell dysfunction and insulin resistance. Int. J. Biochem. Cell Biol. 37: 1595-1608 (2005) https://doi.org/10.1016/j.biocel.2005.04.003
  15. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia. Drugs 57: 19-29 (1999) https://doi.org/10.2165/00003495-199957010-00003
  16. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 15: 792-805 (1992) https://doi.org/10.2337/diacare.15.6.792
  17. Shim YJ, Doo HK, Ahn SY, Kim YS, Seong JK, Park IS, Min BH. Inhibitory effect of aqueous extract from the gall of Rhus chinensis on alpha-glucosidase activity and postprandial blood glucose. J. Ethnopharmacol. 85: 283-287 (2003) https://doi.org/10.1016/S0378-8741(02)00370-7
  18. Youn JY, Park HY, Cho KH. Anti-hyperglycemic activity of Commelina communis L.: inhibition of ${\alpha}$-glucosidase. Diabetes Res. Clin. Pr. 66S: S149-155 (2004)
  19. Nishioka T, Kawabata J, Aoyama Y. Baicalein, an alpha-glucosidase inhibitor from Scutellaria baicalensis. J. Nat. Prod. 61: 1413-1415 (1998) https://doi.org/10.1021/np980163p
  20. Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. Acarbose controls postprandial hyper-proinsulinemia in non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pr. 36: 143-151 (1997) https://doi.org/10.1016/S0168-8227(97)00045-4
  21. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res. Clin. Pr. 46: 23-27 (1999) https://doi.org/10.1016/S0168-8227(99)00061-3
  22. Campbell RK, White JR, Nomura D. The clinical importance of postprandial hyperglycemia. Diabetes Educator 27: 624-637 (2001) https://doi.org/10.1177/014572170102700504
  23. Baron AD. Postprandial hyperglycaemia and ${\alpha}$-glucosidase inhibitors. Diabetes Res. Clin. Pr. 40: S51-55 (1998) https://doi.org/10.1016/S0168-8227(98)00043-6
  24. Kwon CS, Son KH, Kim JS. Effect of Lonicera japonica flower on body weight gain and glucose tolerance in rodents. Food Sci. Biotechnol. 13: 768-771 (2004)
  25. Fujita H, Yamagami J. Fermented soybean-derived touchi-extract with anti-diabetic eftect via alpha-glucosidase inhibitory action in a long-term administration study with KKAy mice. Life Sci. 70: 219-227 (2001) https://doi.org/10.1016/S0024-3205(01)01381-9
  26. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care 22: 960-964 (1999) https://doi.org/10.2337/diacare.22.6.960
  27. Balflour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46: 1025-54 (1993) https://doi.org/10.2165/00003495-199346060-00007
  28. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18: 817-824 (1995) https://doi.org/10.2337/diacare.18.6.817
  29. Seifarth C, Bergmann Y, Bergmann J, Holst JJ, Schmiegel W, Nauck M. Prolonged and enhanced secretion of glucagon like peptide-1 (7-36 amide) after oral sucrose due to alpha glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabetic Med. 15: 485-91 (1998) https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y
  30. Meneilly GS, Ryan EA, Radziuk J. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 23: 1162-1167 (2000) https://doi.org/10.2337/diacare.23.8.1162
  31. Lebovitz HE. ${\alpha}$-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 6:132-145 (1998)
  32. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand. J. Gastroenterol. 30: 892-896 (1995) https://doi.org/10.3109/00365529509101597
  33. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabetic Med. 15: 485-491 (1998) https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y
  34. Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res. Clin. Pr. 40: 63-70 (1998) https://doi.org/10.1016/S0168-8227(98)00045-X
  35. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study Diabetes Res. Clin. Pr. 52: 193-204 (2001) https://doi.org/10.1016/S0168-8227(01)00221-2
  36. Hanefeld M. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J. Diabetes Complicat. 12: 228-237 (1998) https://doi.org/10.1016/S1056-8727(97)00123-2
  37. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Brit. Med. J. 322: 1-6 (2001) https://doi.org/10.1136/bmj.322.7277.1
  38. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care 22: 233-240 (1999) https://doi.org/10.2337/diacare.22.2.233